Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

V Prescribing Information, available at www.OFIRMEV.com or www.cadencepharm.com.

Non-GAAP Financial Measures This press release provides financial measures for net revenue, cost of sales, gross margin, net loss and basic and diluted loss per share that exclude specifically identified non-routine items, and are therefore not calculated in accordance with accounting principles generally accepted in the United States ("GAAP"). Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance that enhances management's and investors' ability to evaluate and compare Cadence's operating results.

These non-GAAP financial measures are not intended to be used in isolation and should not be considered a substitute for any other performance measure determined in accordance with GAAP. Investors and potential investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool, including that other companies may calculate similar non-GAAP financial measures differently than Cadence, limiting their usefulness as a comparative tool. Cadence compensates for these limitations by providing specific information regarding the GAAP amount excluded from the non-GAAP financial measures. Cadence further compensates for the limitations of its use of non-GAAP financial measures by presenting comparable GAAP measures more prominently. Investors and potential investors are encouraged to review the calculation of non-GAAP financial measures contained within this press release with Cadence's GAAP net income and basic and diluted loss per share.

About Cadence Pharmaceuticals, Inc.Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... received a $451,781 Air Force Office of Scientific Research ... and nano-scale level that will provide clues for predicting ... and Aerospace Engineering, said the new technology and process ... of an aircraft,s wing., "We,ll be able to determine ... at it on this scale," Huang said. "Certain patterns ...
(Date:10/17/2014)... SAN DIEGO and HILDEN, ...   , Translational research ... new capabilities being presented at the American Society ... Volume of 250,000-plus DNA samples linked to Ingenuity ... superior depth for genomic analysis  Ingenuity ...
(Date:10/17/2014)... October 17, 2014 Bioquell, provider ... upon by health facilities around the world to ... being treated. Among the many places the hydrogen ... Health Presbyterian Hospital Dallas and at the National ... vapor-producing robots have been utilized to decontaminate patient ...
(Date:10/17/2014)... 17, 2014 The global SWIR market ... analysis and forecast of revenue. This market is valued ... reach $97.9 million by 2019, at a CAGR of ... TOC of the global SWIR market report, to get ... provides a glimpse of the segmentation of the market, ...
Breaking Biology Technology:UT Arlington project to detect possible damages in aircraft parts early in process 2QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 2QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 3QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 4QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 5QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 6Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 2Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 3Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 4Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 5Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 6The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 2The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 3
... Therapeutics Corporation today,announced that Blake M. Paterson M.D., ... in Bioscience Award from the Greater Baltimore Council.,Dr. ... nominees,submitted by businesses, bioscience advocates, higher education,institutions and ... Dr. Paterson has received this award from the ...
... March 18 Caliper Life,Sciences, Inc. (Nasdaq: ... the,Lehman Brothers Global Healthcare Conference in Miami, will ... EDT. Kevin Hrusovsky, President and CEO of,Caliper, will ... The live,webcast can be accessed at, http://cc.talkpoint.com/LEHM002/031808a_jw/default.asp?entity=Caliper . ...
... Three biotech CEOs and,the president of one ... by the Greater Baltimore Committee as winners of ... the 2008 Greater Baltimore Region Bioscience Awards are:, ... E. Askew, President & CEO, CSA,Medical, Inc. Askew,s ...
Cached Biology Technology:Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award 2Three CEOs and University President Named Winners of Greater Baltimore Committee's 2008 Baltimore Region Bioscience Awards 2
(Date:10/15/2014)... pneumonia in female mice to an enzyme activated by ... more resistant to respiratory infections than males. Now, an ... to bacterial pneumonia in female mice is linked to ... show that this enzyme is ultimately activated by the ... team, lead by Professor Lester Kobzik at the Harvard ...
(Date:10/15/2014)... Rosenstiel Award for Distinguished Work in Biomedical Science by ... of genomic instability and its implications for the immune ... to win the Rosenstiel Award; the first, Rod McKinnon, ... the Charles A. Janeway Professor of Pediatrics and Professor ... at the Howard Hughes Medical Institute at Boston Children,s ...
(Date:10/14/2014)... discriminating thieves, prostate cancer tumors scavenge and hoard copper ... such avarice may be a fatal weakness. , ... kill prostate cancer cells by delivering a trove of ... diseased cells brimming with the mineral, leaving non-cancer cells ... already commercially available for other uses, could soon be ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2
... issues, 100 percent fruit and vegetable juices do help reduce ... conclusion is the result of a European study designed to ... significant role in reducing risk for both cancer and cardiovascular ... are comparable in their ability to reduce risk compared to ...
... created from poultry feathers may add value to ... environmental problem of plastic waste. , According to ... million tons of non-biodegradable plastic waste ends up ... of biological systems engineering at Virginia Tech, is ...
... to process information more chaotically than has long been ... by scientists at the University of Bonn. The passing ... they show, occur exclusively at the synapses, i.e. the ... that the neurons release their chemical messengers along the ...
Cached Biology News:100 percent juices found as beneficial to health as fruits and vegetables 2Researcher examines polymers created with poultry feathers 2Brain works more chaotically than previously thought 2Brain works more chaotically than previously thought 3